Model AER-601 - Inhaled Glucagon-like Peptide-1 (GLP-1) Analog
We have completed toxicology studies for AER-601. The product candidate is ready to advance into Phase 1 studies. AER-601 is delivered via our AFINA smart inhaler to help individuals with type 2 diabetes (T2D) achieve a superior level of postprandial glucose control and avoid undesirable gastrointestinal side effects associated with injectable treatments.
-
Most popular related searches
Product Details
The smart inhaler enables pulsatile and flexible delivery of lower GLP-1 dosing:
- Flexible, convenient dosing
- Improved safety profile
Why AER-601?
A large number of individuals with T2D experience postprandial hyperglycemia (PPH - hyperglycemia after meals) despite the current standard of care. Current treatment guidelines for T2D recommend GLP-1 as one of the non-insulin medications to control both basal and postprandial hyperglycemia. Approved therapies are mainly effective in controlling only the basal component, creating a significant unmet need for an alternative to address postprandial hyperglycemia. The inability to control PPH beyond the first decade after diagnosis leads to long-term consequences, including weight gain on insulin therapy, an inability to achieve HbA1c goals over time, and increased microvascular complications. ² ³ 4
Customer reviews
No reviews were found for Model AER-601 - Inhaled Glucagon-like Peptide-1 (GLP-1) Analog. Be the first to review!